The conversation around autism and its causes is evolving, but recent announcements have sparked controversy and division among parents and health advocates.
In New Jersey, Susan Coll-Guedes, a mother of three children on the autism spectrum, reflects on her own journey as well as those of many families dealing with similar concerns.
Coll-Guedes became increasingly worried during her second pregnancy in 2011, pondering if bottled water was safer than tap water and fearing that vaccinations might lead to her child developing autism.
Her concerns were rooted in the rising number of autism diagnoses in New Jersey, especially since her first child had already been diagnosed with autism and Down Syndrome.
Eventually, all three of her children received an autism diagnosis, prompting Coll-Guedes to recognize patterns of behavior in herself and her husband that indicated they might also be on the spectrum, despite never being formally diagnosed.
As she has moved toward acceptance of her family’s situation, she has begun advocating for better understanding and improved resources for those in the autism community.
However, she feels disheartened by the blame and confusion that has emerged following an announcement from the Trump administration linking acetaminophen use during pregnancy to autism.
This claim has faced significant scrutiny, with many researchers disputing the evidence behind it.
The administration also announced the approval of leucovorin, a drug aimed at treating some symptoms of autism, drawing further criticism for the lack of proven effectiveness and scientific backing.
In Coll-Guedes’ view, these sensationalized claims detract attention from critical research into the actual causes of autism, which involve a complex interplay of genetic and environmental factors.
She advocates for greater empathy and a collective effort to enhance support for individuals with autism rather than getting caught up in contentious debates.
“Connecting with real people who have lived experiences is crucial,” she emphasized.
Research on autism is ongoing, with the CDC reporting that approximately 1 in 31 children in the United States are diagnosed with the disorder by age eight.
The breadth of symptoms varies widely among those diagnosed, highlighting the need for individualized approaches to treatment and support.
Kristen Lyall, an associate professor at Drexel University, has been examining autism for years, focusing on potential risk factors during pregnancy, including maternal health and environmental influences.
Lyall noted that while the relationship between acetaminophen and autism has been studied previously, recent large-scale studies, such as one involving over 2 million Swedish children, found no increased risk of autism associated with its use.
Instead, she argues that researchers should focus on the reasons mothers may need this medication during pregnancy, such as chronic health issues, and how those issues might correlate with autism.
The discourse surrounding autism and treatment options is complicated.
Following the recent FDA approval of leucovorin, many parents are eager to explore this new avenue, seeking solutions for their children who may not have responded to previous therapies.
David Mandell, director of the Penn Center for Mental Health, emphasizes the importance of rigorous scientific research before endorsing such treatments.
He explains that, without strong evidence supporting leucovorin’s efficacy for autism symptoms, healthcare providers must tread carefully.
The challenge lies in addressing the pressures faced by parents who feel they have exhausted other options and are looking for any potential solution.
“I don’t blame parents for wanting to try something new,” Mandell remarked, acknowledging their desperation.
The tension between the desire for treatment and the need for careful medical guidance underscores the broader frustrations within the autism community.
In response to the administration’s announcements, Autism New Jersey swiftly communicated evidence-based information, emphasizing existing scientific findings to quell misinformation.
However, their messages have elicited a range of reactions, from support to criticism, highlighting the divided perspectives within the community.
Some families expressed deep disappointment in the organization’s approach, feeling it undermined hope sparked by the administration’s focus on autism.
Executive director Suzanne Buchanan stated that their commitment to science aims to reassure families that they can trust the information provided.
As the divide continues, it has become evident that the community’s voices must be united in the quest for solutions while navigating the available research.
Community advocate Jessica McMaster highlights another pressing issue: the variances in resources and support for autistic children across different districts and states.
She urges the focus to shift toward understanding systemic failures that fail to support children effectively and foster their unique abilities.
Coll-Guedes, in her advocacy work, continues to stress the importance of ongoing support and education for families as a crucial element of progress in autism care.
Her vision extends to creating a health system that is equipped to assist young adults with autism as they transition into adulthood while ensuring they lead rich, dignified lives.
“Research is vital, but what we ultimately need are sustainable supports in place,” she concluded.
image source from：whyy
